Former SmithKline VP James Geddes joins monoclonal antibody firm as VP-sales & marketing, therapeutic products. His initial activities at Centocor will focus on prelaunch and launch activities for Centoxin, a product for treatment of septic shock. He is also charged with establishing a U.S.-based therapeutic sales force. Geddes joined SmithKline in 1968 and most recently directed the company's government, customer relations and national accounts programs as a VP in the U.S. Pharmaceuticals Marketing Division of Smith Kline & French.
You may also be interested in...
“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry.
The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.